(R)-Fluoxetina, um inibidor potente e seletivo da recaptação da serotonina, foi sintetizada em seis etapas, 50% de rendimento total e 99% de excesso enantiomérico a partir do benzaldeído via alilação catalítica assimétrica empregando-se o sistema catalítico desenvolvido por Maruoka e colaboradores.
Introduction
The anti-depressants drugs with a 3-aryloxy-3-phenylpropylamine sub-structure (for example, fluoxetine, atomoxetine and nisoxetine) are among the most important pharmaceuticals for the treatment of psychiatric disorders and metabolic problems. 1, 2 In addition, several members of this class have shown promise for the treatment of alcoholism, chronic pain and eating disorders such as obesity and bulimia. [3] [4] [5] Fluoxetine (1) (Figure 1 ), a selective serotonin reuptake inhibitor (SSRI), is widely used in clinical practice for the treatment of depression. In fact, the selective serotonin reuptake inhibitors, and particularly fluoxetine (1) , have become first line drugs in the pharmacotherapy of patients with depression, whereas tricyclic antidepressants are now considered as second-line agents. This is because the drug possesses tolerability and safety advantages over the tricyclic agents. [6] [7] [8] In experimental models of inflammation, fluoxetine (1) has been shown to exert a inflammatory and pain relieving effects. [9] [10] [11] [12] Fluoxetine [trade name Prozac ® ] is currently marketed in its race form, despite studies showing that the two enantiom have different activities and rates of metabolization. 3 Due to its pharmaceutical importance and to different pharmacological profiles of the individ enantiomers, the development of new strategies preparing optically pure fluoxetine (1) has recei growing interest in recent years. 13 Several method enantioselective synthesis of both enantiomers fluoxetine (1) have been reported and chirality has b introduced via enantioselective hydroxylatio enantioselective epoxidation followed by selec epoxide opening, [15] [16] [17] chemical [18] [19] [20] [21] [22] [23] and enzymatic reduction of ketones and β-ketoesters, stereoselec coupling reaction using chiral auxiliary or ch catalyst, 29, 30 as well as enzymatic 31, 32 or chemica resolution of benzylic alcohols.
Among the strategies developed for enantiomeric pure (R)-fluoxetine [(R)-1], Miles and co-workers descr the Ti(O i Pr) 4 /(R)-BINOL asymmetric ene reaction o methylene-2,3-dihydrofuran (prepared in 63% yield f 3-furaldehyde as a 3.5:1 mixture with 3-methylfuran) w benzaldehyde which afforded (R)-fluoxe hydrochloride [(R)-1.HCl] in 6 steps, 56% overall y and >97% ee from 3-furaldehyde. 30 Recently, Shiba and coworkers carried out the total synthesis of fluoxetine (1) in a multigram scale (4 steps, 67% ove Fluoxetine (1) of N-methyl-trans-cinnamamide, followed by regioselective epoxide opening. 16 The development of chiral Lewis acids or bases for the enantioselective catalytic reactions is one of the most important recent advances in asymmetric synthesis. 35, 36 Enantioselective catalytic allylation (ECA) is one of the powerful C-C bond-forming reactions that have attracted considerable attention in asymmetric synthesis. 37 In our recent studies, we have employed ECA for the highly stereoselective synthesis of (R)-argentilactone and (R)-goniothalamin from the propargylic aldehyde 2-octinal and (E)-cinnamaldehyde, respectively.
38-40 Here, we describe a short and high-yielding enantioselective total synthesis of fluoxetine hydrochloride [(R)-1.HCl] from benzaldehyde featuring its enantioselective asymmetric allylation with the Ti(IV)/(R)-BINOL-based catalyst developed by Maruoka and coworkers as the key step.
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Results and Discussion
Our approach to the synthesis of fluoxetine hydrochloride [(R)-1.HCl] centered on the treatment of benzaldehyde (2) with the in situ generated chiral catalyst (R,R)-A ( Figure 2 ) 41 in CH 2 Cl 2 at -20 o C for 36 h, followed by the addition of allyltri-n-butyltin to provide homoallylic alcohol (R)-1-phenyl-but-3-en-1-ol (3) in 90% yield {[α] D +53° (c=1.1, benzene), lit. 42 [a] D -50.5° (c=1.1, benzene) for (S)-isomer, 96% ee} (Scheme 2). The enantiomeric purity of 3 was determined to be >99% ee by chiral HPLC analysis [Chiralcel OD column; Hex:
i PrOH, 98:2, flow rate = 1 mL min 2 Cl 2 )} was carried out by oxidative cleavage according to the Lemieux-Johnson protocol, 43 followed by NaBH 4 reduction of the crude aldehyde (87% overall yield). The secondary amino functionality was introduced next via the corresponding mesylate 5 which was regioselectively prepared in 85% yield via treatment of diol 4 with mesyl chloride (1.0 equiv.) and Et 3 N at 0 o C. However, for preparative purposes mesylate 5 was used in the next step without further purification as it proved to be rather unstable to chromatography on silica gel and storage. It was straightforwardly converted to (R)-N-methyl-3-phenyl-3-hydroxypropylamine (6) in 96% yield upon treatment with aqueous methylamine under reflux. 15 The total synthesis of (R) In summary, (R)-fluoxetine hydrochloride [(R)-1.HCl] has been synthesized in 6 steps, 50% overall yield and 99% ee from benzaldehyde (2). The route described centered around the catalyst (R,
Experimental
General
Reagents and solvents are commercial grade and were used as supplied, except dichloromethane and tetrahydrofuran which were distilled from calcium hydride. Chromatographic separations were performed using 70-230 Mesh silica gel. Thin-layer chromatography was carried out on Macherey-Nagel precoated silica plates (0.25 mm layer thickness). IR spectra were obtained on Nicolet Impact 410 FT (film or KBr).
1 H NMR and To a stirred solution of (R)-1-phenyl-but-3-en-1-ol (3) ( mg, 3.71 mmol) in a mixture of ethyl ether (12 mL) and w (12 mL) was added OsO 4 (28 mg, 0.11 mmol) and the mix was stirred for 10 min at room temperature. Powdered N (1.75g, 8.16 mmol) was then added over a 40 min period stirring was continued for 2h at room temperature. The mix was poured into ethyl ether (200 mL) and aqueous layer extracted with ethyl ether (3 x 50 mL). The organic la were combined and dried with MgSO 4 and filtered. The c hydroxy aldehyde derivative from 3 was used immedia for the preparation of the diol 4. To crude hydroxy aldeh dissolved in THF (23 mL) was added NaBH 4 (532 mg, 1 mmol) at 0 o C. After 12h, the reaction mixture was then tre with NaHCO 3 aqueous saturated solution (100 mL), extracted with ethyl ether (3 x 100 mL). The organic la were combined and dried with MgSO 4 and filtered. Purifica of the residue by chromatography on silica (dichloromethane: methanol = 9:1 as eluent) gave (R phenyl-1,3-propanediol (4) o C for 3h, the mixture was poured into ice water (10 mL), washed with 20% H 2 SO 4 (7 mL, v/v), saturated aqueous NaHCO 3 (10 mL), and brine, and dried over magnesium sulfate. The solvent was evaporated and the crude reaction mixture was diluted with methylamine (10 mL, 40% in water) in THF (10 mL) and then heated at 65 o C for 3 h. After cooling, the solution was diluted with ether, washed with saturated aqueous sodium bicarbonate and brine, and dried with anhydrous potassium carbonate. Concentration to dryness provides the title compound 6 (476 mg, 81%, 2 steps A solution of (R)-N-methyl-3-phenyl-3-hydroxypropylamine (6) (123 mg, 0.75 mmol) in DMSO (7 mL) was added sodium hydride (22 mg, 0.89 mmol) with cooling. The mixture was heated at 80 o C for 1 h. p-Chlorobenzotrifluoride was added and the mixture was heated for 1 h at 80 to 100 o C and cooled. Extractive isolation with ethyl acetate (3 x 50 mL) afforded the free base form of 1 which after concentration, pale yellow oil was obtained. The oil was dissolved in ether and hydrogen chloride gas was bubbled through the solution until white precipitate was formed. The title compound (R)-1.HCl was colleted as a white solid (200 mg, 78%). IR (KBr) ν max /cm 
